|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, apoC-III has also more recently been identified as an important risk factor for cardiovascular disease.
|
31111320 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Mixed dyslipidemia, characterized by elevated triglyceride and apoC-III levels and low HDL cholesterol level, with or without elevated LDL cholesterol, increases cardiovascular disease risk and is commonly treated with combined statin and fibrate therapy.
|
22236405 |
2012 |
|
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A high level of APOC3 expression is an independent risk factor for some lipid metabolism-related diseases, such as cardiovascular disease (CVD), nonalcoholic fatty liver disease (NAFLD) and atherosclerosis (AS).
|
29555504 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Is APOC3 the driver of cardiovascular disease in people with type I diabetes mellitus?
|
31449060 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Increasing evidence has shown that loss-of-function mutations in APOC3 is associated with reduction in plasma triglycerides levels and will confer a benefit in patients at high risk for cardiovascular disease.
|
27624799 |
2016 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, we review the pathophysiological role of apoC-III in TG metabolism and the evidence supporting this apolipoprotein as an emerging target for hypertriglyceridemia (HTG) and associated cardiovascular disorders.
|
26435212 |
2015 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Conclusions HDL particles of larger size and higher concentrations of large HDL and of HDL without apolipoprotein C-III were associated with lower CVD risk, with risk estimates seemingly stronger among participants with lower eGFR.
|
31818211 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Therefore, there appears to be a need for effective TG-lowering agents.<b>Areas covered</b>: This review presents the most recent advances in hypertriglyceridemia treatment; specifically, it discusses the results of clinical trials and critically comments on apolipoprotein C-III inhibitors, angiopoietin-like 3 inhibitors, alipogene tiparvovec, pradigastat, pemafibrate and novel formulations of omega-3 fatty acids.<b>Expert opinion</b>: In the era of extreme lowering of LDL-C levels with several agents, there seems to be space for novel therapeutic options to combat parameters responsible for residual CVD risk, among which are elevated TGs.
|
31738617 |
2020 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Antisense inhibition of apoC-III in preclinical models and in a phase I clinical trial with healthy subjects produced potent, selective reductions in plasma apoC-III and triglyceride, 2 known risk factors for cardiovascular disease.
|
23542898 |
2013 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, apoC-III and ANGPTL3, both of which are now known to associate with increased atherosclerotic cardiovascular diseases, were enriched in patients with CETP-D compared with normolipidemic subjects (35.9 ± 5.3 vs 27.1 ± 3.7, 2.3 ± 1.1 vs 0.4 ± 1.1, respectively; P < .01).
|
30745272 |
2020 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
APOC3 is an important molecule in lipid metabolism that is closely associated with hyperlipidemia and an increased risk of developing CVD.
|
27619170 |
2016 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
To explore the potential usefulness of screening for genetic predictors of cardiovascular disease, we surveyed BioVU, the Vanderbilt University Medical Center's biorepository linked to de-identified electronic health records (EHRs), for APOC3 19X mutations among adult European American patients (> 45 and > 55 years of age for men and women, respectively) with the lowest percentile of TG levels.
|
30255797 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
When put in the context of studies demonstrating significant protection from cardiovascular events in individuals with loss of function variants in the APOC3 gene, our results provide strong evidence that therapies which increase the efficiency of conversion of VLDL to LDL, thereby reducing remnant concentrations, should reduce the risk of cardiovascular disease.
|
30580564 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Apolipoprotein C-III has been referred to as an important participant in the metabolism of triglyceride-rich lipoproteins, leading to hypertriglyceridemia and thereafter cardiovascular disease.
|
27770802 |
2016 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Because serum levels of APOC3 predicted incident CVD events in the CACTI study, inhibiting APOC3 might reduce CVD risk in T1DM patients.
|
31295146 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
ApoCIII and triglyceride (TG)-rich lipoproteins (TRL), particularly, large TG-rich lipoproteins particles, have been described as important mediators of cardiovascular disease (CVD) risk.
|
31247940 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Apolipoprotein C-III (apo C-III) is a marker of cardiovascular disease risk associated with triglyceride (TG)-rich lipoproteins.
|
15576429 |
2005 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Loss-of-function mutations in APOC3 were associated with low levels of triglycerides and a reduced risk of ischemic cardiovascular disease.
|
24941082 |
2014 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
This favourable lipid profile in patients with genetically low apoCIII levels holds promise for current studies investigating the potential of apoCIII inhibition as a novel therapeutic in cardiovascular disease prevention.
|
23701270 |
2014 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
ApoC-III is a critical cardiovascular risk factor, and humans expressing null mutations in apoC-III are robustly protected from cardiovascular disease.
|
28739253 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Serum apoCIII concentration was highly correlated with multiple changes in lipids and lipoproteins that resulted in an adverse cardiovascular disease risk profile.
|
15375785 |
2004 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Variation within and around the apolipoprotein C-III (APOC3) gene has been associated with elevated triglyceride (Tg) levels and cardiovascular disease.
|
11116069 |
2000 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Rs45456595 (CDKN2A, Gly63Arg), rs5128 (APOC3, 3'UTR), and rs72650673 (SH2B3, rs72650673;rs1285539239;s72650673;rs370155845" genes_norm="10019;1124;1284">Glu400Lys) were nominally associated with history of CVD, subclinical CVD, or CVD risk factors (p < 0.010).
|
24725463 |
2014 |
|
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Multiple studies confirmed the correlation between increased apoC-III levels and cardiovascular disease.
|
29547399 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We examined the association of LpPLA2 activity and ApoC3 LOF mutations and incident cardiovascular disease (CVD) (defined as coronary heart disease [CHD] plus ischemic stroke) and all-cause mortality in the biracial longitudinal Atherosclerosis Risk In Communities (ARIC) study.
|
26117401 |
2015 |